Pilot, prospective, monocentric study aimed at evaluating the rate of patients with circulating "cancer cell/macrophage" hybrid cells in the peripheral blood. The study will be conducted on a population of patients with sarcoma and treated in the context of routine care. For each included patient, blood samples will be collected during baseline visit and after the initiation therapy. At the end of the 2nd blood collection, the patient will have completed his participation in the study.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
60
* at Baseline, * after surgery or at the time of post-chemotherapy evaluation.
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, France
Rate of patients with "cancer cell / macrophage" hybrid cells in peripheral blood.
Time frame: 6 months after the end of inclusions
Quantification of circulating hybrid cells in peripheral blood by automatic measurement (Cell Counter Corning) and expressed in number of cells / millilitre of blood.
Time frame: 6 months after the end of inclusions
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.